rupiya.io
⠋Loading...
0%
❯ Evaluating quality metrics...
Torrent Pharma is a leading Indian company in the Pharmaceuticals space, listed on the NSE. The company is a key player in the Pharma — Formulations segment with a strong market position and diversified operations.
Torrent Pharmaceuticals Ltd makes money through Core Business, Other Segments, Exports in Pharma — Formulations. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Metric | 1 Year | 3 Years | 5 Years | 10 Years |
|---|---|---|---|---|
| Sales | — | — | — | — |
| Profit | — | — | — | — |
| Stock Price | — | — | — | — |
| ROE | — | — | — | — |
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹4,172 Cr | ₹4,636 Cr | ₹6,687 Cr |
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹2,491 Cr | ₹2,491 Cr | ₹2,591 Cr | ₹2,660 Cr | ||||||||
| Expenses | ₹1,767 Cr | ₹1,764 Cr | ₹1,800 Cr | ₹1,835 Cr | ||||||||
| Operating Profit | ₹724 Cr | ₹727 Cr | ₹791 Cr | ₹825 Cr |
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹85 Cr | ₹85 Cr | ₹85 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹1,818 Cr | ₹2,406 Cr | ₹3,409 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2015 | ₹599 Cr | ₹-418 Cr | ₹86 Cr | — |
| Mar 2016 | ₹810 Cr | ₹-2,113 Cr | ₹1,212 Cr | — |
| Mar 2017 | ₹2,742 Cr | ₹-869 Cr | ₹-1,435 Cr | — |
| Mar 2018 | ||||
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 |
| Ratio | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 14.5% | 14.1% | 15.1% | — | — | — | — | — | — | — | — | — | — | — | — |
| ROCE % | 16.0% | 15.7% | 16.7% | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt/Equity | 0.5 | 0.4 | 0.5 | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 9.7 | 14.6 | 9.8 | — | — | — | — | — | — | — | — | — |
| Year | Type | Amount (₹) |
|---|---|---|
| FY24 | Final | ₹15.89 |
| FY23 | Final | ₹6.69 |
| FY22 | Interim | ₹17.31 |
| FY21 | Interim | |
| FY20 | Final | |
| FY19 | Interim |
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +7.16% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.69% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -2.61% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +24.63% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +7.59% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.
Deep-dive analysis of Torrent Pharma's competitive moat, management quality, and growth runway available with Premium.
Premium| Expenses | ₹3,216 Cr | ₹3,616 Cr | ₹3,954 Cr |
| Operating Profit | ₹955 Cr | ₹1,020 Cr | ₹2,733 Cr |
| OPM % | 23.0% | 22.0% | 41.0% |
| Other Income | ₹34 Cr | ₹286 Cr | ₹32 Cr |
| Depreciation | ₹87 Cr | ₹191 Cr | ₹238 Cr |
| Interest | ₹59 Cr | ₹175 Cr | ₹184 Cr |
| Profit Before Tax | ₹844 Cr | ₹940 Cr | ₹2,343 Cr |
| Tax | ₹844 Cr | ₹940 Cr | ₹2,343 Cr |
| Net Profit | ₹664 Cr | ₹751 Cr | ₹1,733 Cr |
| EPS (₹) | 19.6 | 22.2 | 51.2 |
| Dividend Payout % | 25% | 25% | 34% |
Register free to see 9 more years.
| OPM % | 29.0% | 29.0% | 31.0% | 31.0% |
| Depreciation | ₹193 Cr | ₹196 Cr | ₹191 Cr | ₹201 Cr |
| Interest | ₹102 Cr | ₹107 Cr | ₹103 Cr | ₹91 Cr |
| Net Profit | ₹292 Cr | ₹287 Cr | ₹378 Cr | ₹386 Cr |
| EPS (₹) | 8.6 | 8.5 | 11.2 | 11.4 |
Register free to see 8 more quarters.
| Borrowings | ₹1,132 Cr | ₹2,740 Cr | ₹2,352 Cr |
| Other Liabilities | ₹1,988 Cr | ₹2,589 Cr | ₹3,040 Cr |
| Total Liabilities | ₹5,022 Cr | ₹7,820 Cr | ₹8,886 Cr |
| Assets |
| Fixed Assets | ₹875 Cr | ₹2,833 Cr | ₹2,859 Cr |
| Investments | ₹186 Cr | ₹298 Cr | ₹780 Cr |
| Receivables | — | — | — |
| Inventory | — | — | — |
| Cash & Equivalents | — | — | — |
| Other Assets | ₹3,427 Cr | ₹4,011 Cr | ₹4,206 Cr |
| Total Assets | ₹5,022 Cr | ₹7,820 Cr | ₹8,886 Cr |
Register free to see 9 more years.
| Mar 2022 |
| Mar 2023 |
| Mar 2024 |
| Mar 2025 |
Register free to see 9 more years.
| — |
| — |
| — |
| Current Ratio | 1.8 | 1.6 | 1.8 | — | — | — | — | — | — | — | — | — | — | — | — |
| Quick Ratio | 1.1 | 1.2 | 1.4 | — | — | — | — | — | — | — | — | — | — | — | — |
| OPM % | 14.0% | 13.7% | 16.2% | — | — | — | — | — | — | — | — | — | — | — | — |
| NPM % | 8.4% | 8.3% | 9.7% | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 17.8 | 17.8 | 15.0 | — | — | — | — | — | — | — | — | — | — | — | — |
| PEG Ratio | 1.3 | 1.6 | 1.6 | — | — | — | — | — | — | — | — | — | — | — | — |
| Asset Turnover | 1.2 | 1.0 | 0.5 | — | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 7.6 | 10.5 | 10.4 | — | — | — | — | — | — | — | — | — | — | — | — |
Register free to see 12 more years of ratio trends.